Proton Pump Inhibitors and Histamine-2 Receptor Antagonists Are Associated With Hip Fractures Among At-Risk Patients
To access this article, please choose from the options below
View this article's video abstract at www.gastrojournal.org.
Conflicts of interest The authors disclose the following: Dr Corley has received research funding (unrelated to the current project) from Wyeth Pharmaceuticals, which manufacturers a proton pump inhibitor. He does not have stock, consulting arrangements, or any other relationship with Wyeth. The remaining authors disclose no conflicts.
Funding Supported by a Kaiser Permanente Community Benefits Grant and US National Institutes of Health grant R01 DK63616 (to D.A.C.).
PII: S0016-5085(10)00488-9
doi:10.1053/j.gastro.2010.03.055
© 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.

